News

Banzai Connections: Join the Upcoming Conference Call for Results

Banzai Connections: Join the Upcoming Conference Call for Results

Banzai Announces Third Quarter Results Conference Call

SEATTLE, Oct. 30, 2024 — Banzai International, Inc. (NASDAQ: BNZI), a prominent name in marketing technology known for its innovative solutions, is poised to connect with stakeholders through a conference call scheduled for Thursday, November 14, 2024, at 5:30 p.m. Eastern Time. This call will focus on the company’s third-quarter results ending September 30, 2024. Key topics will include insights into expanding partnerships and updates on debt payoff and restructuring efforts, reflecting Banzai's commitment to ongoing growth.

Who Will Host the Call?

The conference call will be led by Banzai's Founder and CEO, Joe Davy, alongside Interim CFO Alvin Yip. They will provide an overview of the company's financial performance and strategic advancements followed by a session for questions from participants. This interactive component aims to engage stakeholders and address any inquiries about the latest developments at Banzai.

How to Join the Conference Call

To participate in the call, please use the access details outlined below:

Date: Thursday, November 14, 2024
Time: 5:30 p.m. Eastern Time, 2:30 p.m. Pacific Time

Toll-free dial-in number: 1-877-425-9470
International dial-in number: 1-201-389-0878
Conference ID: 13749747

It’s advised to join the call 5-10 minutes early to ensure a smooth connection. An operator will be there to register your name and organization.

Live Broadcast and Replay Options

The conference call will not only be broadcast live but will also be available for replay afterward. Those unable to join live can listen to the archived session via the Banzai website. Additionally, here are the replay access details:

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 13749747

Mark your calendars; the replay will be accessible until February 14, 2025, allowing ample opportunity for review.

About Banzai International, Inc.

Banzai is on a mission to empower businesses with its cutting-edge marketing and sales solutions. Serving a wide range of clients, including notable names like Square, Hewlett Packard Enterprise, and Thermo Fisher Scientific, Banzai enables organizations to engage effectively with both new and existing customers. With a focus on delivering measurable outcomes, Banzai’s services are designed to help businesses navigate the complexities of marketing in today's dynamic environment. For detailed insights and additional information, interested parties can explore the company’s offerings at www.banzai.io.

Frequently Asked Questions

What is the purpose of the upcoming conference call?

The call aims to discuss Banzai's Q3 results, partnerships, and financial strategies.

Who should attend the Banzai conference call?

Investors, analysts, and stakeholders interested in Banzai's performance and strategy should attend.

How can I access the live conference call?

Dial in using the provided toll-free or international numbers on the specified date and time.

Will the call be available for replay?

Yes, a replay will be available after the event, accessible until February 14, 2025.

Where can I find more information about Banzai's services?

More information is available directly on Banzai's website, reflecting their commitment to assisting businesses of all sizes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

AgEagle Aerial Systems Welcomes Kevin Lowdermilk to the Board

Updated Category News Views 103

AgEagle Aerial Systems Welcomes Kevin Lowdermilk to the Board AgEagle Aerial Systems Inc. (NYSE: UAVS), renowned for its top-tier unmanned aerial systems (UAS), is excited to announce the recent addition of Kevin Lowdermilk to its board of directors. His appointment, effective as of late October, marks a strategic enhancement to the company's leadership team, ensuring...

Continue Reading
Natera's Growth Continues Amid Legal Challenges and Market Wins

Updated Category News Views 413

Natera Faces Legal Challenges with Strong Market Performance Natera, Inc. (NASDAQ: NTRA) is a leader in the genetic testing industry, known for its groundbreaking contributions to oncology and women’s health. Recently, the company encountered an unfavorable jury decision in a legal battle concerning false advertising claims made against Guardant Health (NASDAQ: GH). The...

Continue Reading
Spreedly Sees Unprecedented Growth in Open Payments Sector

Updated Category News Views 110

Spreedly Surges Ahead in Open Payments Innovation Spreedly, a prominent leader in open payments, has recently showcased remarkable progress in revenue and customer expansion, marking a new chapter in the payment processing industry. With a growing clientele that spans across varied sectors, the company is redefining how digital transactions are handled worldwide. Key...

Continue Reading
Shelley Joyce Takes the Helm as CTO at TSG, Ramping Up Innovation

Updated Category News Views 431

TSG Appoints Shelley Joyce as New Chief Technology Officer In a significant move to enhance its technology initiatives, TSG (The Strawhecker Group) has announced the appointment of Shelley Joyce as the Chief Technology Officer (CTO). With her extensive background in the payments industry, Shelley is set to lead TSG’s technological advancements and cater to the evolving...

Continue Reading
Equillium Plans Engaging Event for Ulcerative Colitis Insights

Updated Category News Views 121

Equillium's Upcoming Event on Ulcerative Colitis Equillium, Inc. (NASDAQ: EQ), a biotechnology company focused on developing innovative therapeutics for autoimmune and inflammatory diseases, has announced an exciting virtual event featuring prominent thought leaders in the field of ulcerative colitis (UC). This event is scheduled for a Wednesday in November at 12 PM ET....

Continue Reading